| name | endo-pharmacologic-treatment-tg-over-500 |
| description | Recommends pharmacologic treatment as adjunct to diet and exercise to prevent pancreatitis in adults with fasting triglyceride levels >500 mg/dL. Triggered when evaluating a patient with an endocrine disorder who presents with fasting TG >500 mg/dL (severe hypertriglyceridemia) and no contraindication to pharmacologic therapy. |
Pharmacologic treatment for severe hypertriglyceridemia to prevent pancreatitis
STEP 1 — Gather Information
Collect fasting triglyceride level, confirm endocrine disorder diagnosis, assess for diabetes control, alcohol intake, medications that raise TG (e.g., estrogen, bile acid sequestrants), diet, weight, and pancreatitis symptoms; obtain baseline liver enzymes and creatinine kinase if considering fibrate or statin.
STEP 2 — Rule In / Rule Out
Is fasting triglyceride level >500 mg/dL? If yes, proceed to pharmacologic treatment consideration; if no, do not initiate pharmacologic therapy solely for pancreatitis prevention (manage per general lipid guidelines).
STEP 3 — Classify or Stratify
Stratify by TG level: 500–1000 mg/dL (moderate-severe) vs >1000 mg/dL (very severe), as response to medications may be inadequate above 1000 mg/dL requiring intensified diabetes control, diet, and weight loss.
STEP 4 — Decide
For TG 500–1000 mg/dL: initiate pharmacologic therapy (e.g., fibrate, EPA ethyl ester 4 g/day, or statin if ASCVD/diabetes indications) as adjunct to low-simple-sugar, low-alcohol diet and exercise; for TG >1000 mg/dL: prioritize aggressive diabetes control, dietary fat restriction (<20% kcal), weight loss, and consider pharmacologic therapy while acknowledging limited efficacy; reassess TG in 2–4 weeks.
Clinical Guardrails / Mimics / Pitfalls
Do not use bile acid sequestrants when TG>500 mg/dL (contraindicated due to potential TG rise); avoid estrogen-containing therapies that exacerbate hypertriglyceridemia; do not rely on acute plasmapheresis or insulin infusion as first-line for TG-induced pancreatitis; monitor for myopathy when combining statin with fibrate (especially gemfibrozil); avoid niacin in diabetes due to worsening glycemic control.
Concrete Clinical Example
A 45-year-old woman with Cushing syndrome has fasting TG 620 mg/dL, BMI 30, HbA1c 6.0%, and mild epigastric discomfort. After confirming TG>500 and excluding secondary causes, she is started on fenofibrate 145 mg daily, a diet low in refined sugars and alcohol, and a goal of 5–10% weight loss; at 6-week follow-up TG is 280 mg/dL and symptoms resolve.
Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674
TODO: consider adding scripts/calc.py for the endo-pharmacologic-treatment-tg-over-500 calculator
